Diagnosing hypermobile Ehlers–Danlos syndrome (hEDS) remains challenging, despite new 2017 criteria. Patients not fulfilling these criteria are considered to have hypermobile spectrum disorder (HSD). Our first aim was to evaluate whether patients hEDS were more severely affected and had higher prevalence of extra-articular manifestations than HSD. Second aim was to compare their outcome after coordinated physical therapy. Patients fulfilling hEDS/HSD criteria were included in this real-life prospective cohort (November 2017/April 2019). They completed a 16-item Clinical Severity Score (CSS-16). We recorded bone involvement, neuropathic pain (DN4) and symptoms of mast cell disorders (MCAS) as extra-articular manifestations. After a standardized initial evaluation (T0), all patients were offered the same coordinated physical therapy, were followed-up at 6 months (T1) and at least 1 year later (T2), and were asked whether or not their condition had subjectively improved at T2. We included 97 patients (61 hEDS, 36 HSD). Median age was 40 (range 18–73); 92.7% were females. Three items from CSS-16 (pain, motricity problems, and bleeding) were significantly more severe with hEDS than HSD. Bone fragility, neuropathic pain and MCAS were equally prevalent. At T2 (20 months [range 18–26]) 54% of patients reported improvement (no difference between groups). On multivariable analysis, only family history of hypermobility predicted (favorable) outcome (p = 0.01). hEDS and HDS patients showed similar disease severity score except for pain, motricity problems and bleeding, and similar spectrum of extra-articular manifestations. Long-term improvement was observed in > 50% of patients in both groups. These results add weight to a clinical pragmatic proposition to consider hEDS/HSD as a single entity that requires the same treatments.
Background:Opioids prescription for non-cancer pain has come under intense scrutiny as opioids abuse has become a major public health issue. Chronic opioid use is common among patients with rheumatic diseases. There are data showing that opioids are associated with a higher mortality in osteoarthritis patients receiving joint replacement. However, more data are needed on opioids use and prescription in rheumatology inpatients [1].Objectives:To evaluate inpatient characteristics on opioid prescription at discharge from our rheumatology ward in 2017 and 2019.Methods:We prospectively recorded analgesics prescription patterns of paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), weak opioids (tramadol/codeine) and strong opioids at discharge for all patients hospitalized in the Rheumatology Department from May to October 2017 and from October to December 2019. Statistical analyses consisted of descriptive statistics and univariate/multivariate logistic regression. P≤0.05 was considered statistically significant.Results:We analysed 240 hospital inpatient stays of 223 patients (mean age 64 years). At discharge, 25% of patients were respectively on weak opioids (tramadol/codeine) and 23% were on strong opioids, at a fixed dosage.Overall, a minority of patients were on opioids monotherapy (20% for weak opioids and 22% for strong opioids), the majority receiving combined treatments with WHO class I analgesics.The highest rate of opioids prescription at discharge was observed in patients hospitalized for severe low back pain (40%) and osteoporotic fracture (30%). At discharge, all patients transferred to a nursing home and 35% of patients transferred to a transitional care unit were on opioids compared to only 16% of the patients discharged home. The majority of patients being on opioids when transferred to a transitional care unit were prescribed opioids when discharged home (86%).Opioids prescription at discharge was negatively associated with home discharge in multivariate analysis (0.23, 0.09 to 0.55, adjusted OR, 95%CI), Table 1. There was no significant association between inpatient stay length and opioids prescription at discharge. Between 2017 and 2019, we observed a non-significant decrease in opioids prescription at discharge (absolute difference -4.7%).Conclusion:Analysis of opioids prescription from a Swiss rheumatology service of a tertiary hospital show frequent opioids prescription at inpatients discharge, mainly for non-inflammatory disorders. Opioids prescription negatively predict home discharge.References:[1] Kim, S.C., Solomon, D.H. Towards defining the safer use of opioids in rheumatology. Nat Rev Rheumatol 16, 71–72 (2020).Disclosure of Interests:Alexandre Dumusc: None declared, Flore Valerio: None declared, Thomas Hügle Grant/research support from: Abbvie, Novartis, Consultant of: Abbvie, Pfizer, Novartis, Roche, Lilly, BMS
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.